New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
06:33 EDTHZNPHorizon Pharma reports Q4 non-GAAP EPS (34c), consensus (47c)
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
07:30 EDTHZNPHorizon Pharma initiated with a Buy at Mizuho
Subscribe for More Information
October 7, 2015
07:36 EDTHZNPInfectious Diseases Society of America to hold a conference
Subscribe for More Information
07:05 EDTHZNPHorizon says 3 advisory firms recommend Depomed holders vote FOR solicitation
Subscribe for More Information
October 6, 2015
10:43 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
07:23 EDTHZNPAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
10:24 EDTHZNPOptions with decreasing implied volatility
Options with decreasing implied volatility: HZNP EMES BIB RJET VIX NVAX SRPT GLNG VRX
07:10 EDTHZNPHorizon Pharma announces expansion, relocation of U.S. headquarters
Subscribe for More Information
October 2, 2015
07:04 EDTHZNPHorizon Pharma enters settlement pact with Actavis Labs over RAYOS
Subscribe for More Information
September 30, 2015
10:36 EDTHZNPOptions with increasing implied volatility
Subscribe for More Information
08:30 EDTHZNPDepomed should be bought at current levels, says Roth Capital
Subscribe for More Information
September 29, 2015
12:58 EDTHZNPHorizon Pharma's volatility at 52-week high
Subscribe for More Information
10:48 EDTHZNPOptions with increasing implied volatility
Subscribe for More Information
05:05 EDTHZNPStocks with implied volatility movement; HZNP VRX
Stocks with implied volatility movement; Horizon Pharma (HZNP) 132, Valeant (VRX) 98 according to iVolatility.
September 28, 2015
16:19 EDTHZNPOn The Fly: Top stock stories for Monday
Stocks on Wall Street were sharply lower as investors continue to worry about the health of China's economy and continue to flee the biotech sector. The iShares NASDAQ Biotechnology Index (IBB) was down 6.33% today and is down about 18.5% since September 21, when Democratic presidential candidate Hillary Clinton pledged to take action against the high prices of specialty drugs. Adding to the tentative mood among investors was noted investor Carl Icahn's preview for a presentation that will be made available on his site tomorrow, entitled "Danger Ahead." The preview includes several cautious comments that the billionaire has publicly made recently regarding his concerns about the high-yield bond market and the stock market. ECONOMIC EVENTS: In the U.S., personal income grew 0.3% in August, versus expectations for it to rise 0.4%. Personal spending rose 0.4% last month, versus expectations for growth of 0.3%. The pending home sales index fell 1.4% in August, missing expectations for it to have risen 0.4%. The Dallas Fed manufacturing outlook survey for September had a reading of -9.5, versus expectations for a reading of -10.0. In China, industrial profits plunged 8.8% in August, adding to the recent string of weak data from the Asian giant. COMPANY NEWS: Apple (AAPL) reported that it set a record by selling more than 13M new iPhone 6s and iPhone 6s Plus models in the first three days after launch of the devices. However, shares of the tech giant slid about 2% to $112.44 following the announcement... Alcoa (AA) shares advanced 52c, or 5.73%, to $9.59 after the company announced that its board has approved a plan to separate into two independent, publicly-traded companies - an Upstream company that will operate under the Alcoa name and a new "Value-Add company" that will provide high-performance, multi-material products whose name will be announced at a later date... Biotech stocks continued recent declines, with Valeant (VRX) dropping 16.6% after a group of Democratic congressmen urged additional scrutiny of the company's "price hike" business model, while Epizyme (EPZM) and NewLink (NLNK) fell a respective 27% and 21% after presenting data at the 2015 European Cancer Congress... Shares of both Energy Transfer Equity (ETE) and Williams (WMB) fell after they announced a combination deal valued at approximately $37.7B, including the assumption of debt and other liabilities. Under the terms of their deal, an affiliate of ETE will acquire Williams at an implied current price of $43.50 per Williams share, the companies said. In late June, Energy Transfer Equity made a proposal to merge with Williams in an all-equity transaction valued at that time at $53.1B, including the assumption of debt and other liabilities. Under that prior merger proposal, ETE would have acquired all of the outstanding common stock of Williams at an implied price of $64 per Williams share, which represented a 32.4% premium to Williams' common share closing price as of June 19. Energy Transfer Equity shares closed down $2.95, or 12.69%, to $20.29 after announcing today's revised deal, while Williams dropped $5.03, or 12.09%, to close at $36.57. MAJOR MOVERS: Among the notable gainers was Republic Airways (RJET), which surged $2.38, or 81.8%, to $5.29 after announcing that the company and Teamsters Local 357 have reached a consensual tentative agreement on the terms of a new three-year contract for the 2,100 Republic pilots represented by the International Brotherhood of Teamsters. Also higher was Media General (MEG), which gained $2.49, or 22.3%, to $13.64 after Nexstar (NXST) proposed a cash-and-stock deal to acquire the company for $14.50 per share, which Media General said it would "carefully review." Additionally, Sanchez Energy (SN) rose 4.5% to $5.57 after agreeing to sell certain Eagle Ford Shale midstream assets to Sanchez Production Partners (SPP) for $345M. Among the noteworthy losers was Huntsman (HUN), which plunged $3.99, or 28.7%, to $9.92 after warning that headwinds would impact its third quarter earnings. Also lower were shares of Depomed (DEPO) and Horizon Pharma (HZNP), falling a respective 22% and 21%, after Depomed continued its criticism of Horizon's hostile takeover bid for the company. INDEXES: The Dow fell 312.78, or 1.92%, to 16,001.89, the Nasdaq lost 142.53, or 3.04%, to 4,543.97, and the S&P 500 dropped 49.57, or 2.57%, to 1,881.77.
10:20 EDTHZNPOptions with increasing implied volatility
Subscribe for More Information
06:44 EDTHZNPDepomed issues statement on ISS report
Depomed (DEPO) issued the following statement regarding a report by Institutional Shareholder Services' on Horizon Pharma's (HZNP) solicitation to call two special meetings of Depomed's shareholders. Depomed commented, "The ISS recommendation does not change the fact that we believe Horizon's offer does not reflect the value inherent in Depomed's business nor Depomed's compelling prospects for long-term growth and value creation, and therefore is not in the best interests of shareholders... We strongly believe Depomed shareholders are being misled by Horizon and are entitled to know the facts. First, based on Friday's closing price of Horizon stock, Horizon's all-stock exchange offer has a current value of only $21.64 per Depomed share, nowhere near the $33.00 a share that Horizon continues to disingenuously tout in its communications to Depomed shareholders. Second, Horizon has misleadingly announced false deadlines to submit proxies. To be clear, Depomed's Board of Directors has set record dates for October 29 and November 13, 2015 and there is no deadline approaching for Depomed shareholders to submit proxy cards to call a special meeting. Moreover, there is absolutely no requirement for Depomed shareholders to take any action until after the October 29 and November 13, 2015 record dates."
September 25, 2015
12:38 EDTHZNPOptions with increasing implied volatility
Subscribe for More Information
08:02 EDTHZNPHorizon Pharma wins positive CHMP opinion for urea cycle disorder treatment
Horizon Pharma announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion at its plenary monthly meeting in September recommending a centralized marketing authorization for RAVICTI Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients greater than two months of age with Urea Cycle Disorders. Detailed recommendations for the use of RAVICTI will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission. The adopted positive opinion will be considered by the European Commission for a binding decision to be issued for the granting of a centralized marketing authorization within 60 to 90 days from the date of adoption of the opinion.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use